Sinocelltech Group

Sinocelltech Group Gross Margin

Gross Margin of Sinocelltech Group (688520.SS) as of Oct 25, 2026.

Gross Margin

-

Last updated:

Gross Margin of Sinocelltech Group is 2026 - . Gross Margin of Sinocelltech Group was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sinocelltech Group Stock analysis

What does Sinocelltech Group do? Sinocelltech Group Ltd, based in Beijing, China, operates in the Health Care sector with a focus on biotechnology. The company develops and manufactures biopharmaceutical products, including monoclonal antibodies, recombinant proteins, and vaccines. Key products are SCT800, SCT200, SCT-I10A, SCT400, SCT510, SCT1000, and SCT630. Sinocelltech employs 1,868 full-time staff and is listed on the stock market since June 22, 2020. It also engages in asset leasing and payment collection services. Sinocelltech Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sinocelltech Group stock

On Eulerpool you can find the complete historical development of Gross Margin Sinocelltech Group since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Sinocelltech Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sinocelltech Group

All Key Metrics — Sinocelltech Group